Gilead takes a hit af­ter a close­ly-watched Covid-19 tri­al of remde­sivir is qui­et­ly ter­mi­nat­ed, rais­ing fresh doubts

Shares of Gilead took a 3% hit $GILD Wednes­day af­ter re­searchers not­ed that they had sus­pend­ed one of the close­ly-watched Covid-19 stud­ies for remde­sivir in Chi­na.

Ini­tial­ly high­light­ed in a note from RBC Cap­i­tal, an up­date on clin­i­cal­tri­als.gov to­day stat­ed that the Phase III for mild to mod­er­ate pa­tients had to be ter­mi­nat­ed due to a lack of pa­tients to en­roll. The spon­sor is Cap­i­tal Med­ical Uni­ver­si­ty with the Chi­nese Acad­e­my of Med­ical Sci­ences list­ed as a col­lab­o­ra­tor.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER